[Clinical evaluation of schizophyllan (SPG) in advanced gastric cancer (the second report)--a randomized controlled study]

Gan To Kagaku Ryoho. 1985 Jun;12(6):1272-7.
[Article in Japanese]


We reported previously that Schizophyllan (SPG) combined with MMC + 5-FU (MF regimen) or Tegafur (F regimen) had a significant life-prolonging effect over chemotherapeutic regimens in patients with inoperable and recurrent gastric cancer in a randomized controlled study. In the present paper, we have further investigated the effect of SPG on life-span followed-up for more than 2 years. A significant life-prolonging effect of SPG was reconfirmed in patients given either the MF regimen (154 patients) or the F regimen (213 patients). Thus, SPG combined with chemotherapeutics has proved to be useful for treating patients with inoperable and recurrent gastric cancer, resulting in a significant prolongation of life-span without serious side effects despite having no influence on tumor size.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Clinical Trials as Topic
  • Drug Administration Schedule
  • Fluorouracil / administration & dosage
  • Glycosaminoglycans / therapeutic use*
  • Humans
  • Mitomycin
  • Mitomycins / administration & dosage
  • Random Allocation
  • Sizofiran / administration & dosage
  • Sizofiran / therapeutic use*
  • Stomach Neoplasms / drug therapy*
  • Tegafur / administration & dosage


  • Glycosaminoglycans
  • Mitomycins
  • Tegafur
  • Mitomycin
  • Sizofiran
  • Fluorouracil